Johnson & Johnson has to face US antitrust claims over Stelara patent, judge rules
MLex Summary: CareFirst has standing to bring US antitrust claims over Johnson & Johnson’s patent covering a method for using the drug ustekinumab, according to a federal judge. “The alleged harm—the...To view the full article, register now.
Already a subscriber? Click here to view full article